4.7 Review

Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

期刊

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2022.908389

关键词

tumor microenvironment; vascular normalization; immune checkpoints; hypoxia; immunotherapy; angiogenesis; immune cell infiltrate

向作者/读者索取更多资源

Immunotherapies modulate immune cells to target cancer cells, but the immunosuppressive nature of the tumor microenvironment (TME) limits their efficacy. TME normalization is a treatment strategy to reverse abnormalities in tumor blood vessels, resulting in enhanced antitumor immunity. Understanding how immunotherapies themselves normalize the TME is currently unclear.
Immunotherapies modulate the function of immune cells to eradicate cancer cells through various mechanisms. These therapies are successful across a spectrum of cancers, but they are curative only in a subset of patients. Indeed, a major obstacle to the success of immunotherapies is the immunosuppressive nature of the tumor microenvironment (TME), comprising the stromal component and immune infiltrate of tumors. Importantly, the TME in most solid cancers is characterized by sparsely perfused blood vessels resulting from so-called pathological angiogenesis. In brief, dysregulated development of new vessels results in leaky tumor blood vessels that inefficiently deliver oxygen and other nutrients. Moreover, the occurrence of dysregulated fibrosis around the lesion, known as pathological desmoplasia, further compresses tumor blood vessels and impairs blood flow. TME normalization is a clinically tested treatment strategy to reverse these tumor blood vessel abnormalities resulting in stimulated antitumor immunity and enhanced immunotherapy efficacy. TME normalization includes vascular normalization to reduce vessel leakiness and reprogramming of cancer-associated fibroblast to decompress vessels. How immunotherapies themselves normalize the TME is poorly understood. In this review, we summarize current concepts and progress in TME normalization. Then, we review observations of immunotherapy-induced TME normalization and discuss the considerations for combining vascular normalizing and immunotherapies. If TME could be more completely normalized, immunotherapies could be more effective in more patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity

Natasha Ustyanovska Avtenyuk, Ghizlane Choukrani, Emanuele Ammatuna, Toshiro Niki, Ewa Cendrowicz, Harm Jan Lourens, Gerwin Huls, Valerie R. Wiersma, Edwin Bremer

Summary: In this study, Gal-9 treatment was found to induce significant membrane alterations in cancer cells by externalizing phosphatidyl serine (PS) and downregulating the anti-phagocytic regulator CD47. It was also shown to trigger trogocytosis and enhance antibody-dependent cellular phagocytosis of cancer cells by activating neutrophils and mobilizing granules. Moreover, Gal-9 treatment resulted in decreased cancer cell adhesion and potent cytotoxicity mediated by neutrophils.

BIOMEDICINES (2022)

Article Oncology

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Ewa Cendrowicz, Lisa Jacob, Shirley Greenwald, Ami Tamir, Iris Pecker, Rinat Tabakman, Lucy Ghantous, Liat Tamir, Roy Kahn, Jasmine Avichzer, Alexandra Aronin, Shira Amsili, Elina Zorde-Khvalevsky, Yosi Gozlan, Martijn Vlaming, Gerwin Huls, Tom van Meerten, Michal Elhalel Dranitzki, Adam Foley-Comer, Yaron Pereg, Amnon Peled, Ayelet Chajut, Edwin Bremer

Summary: DSP107 effectively (re)activates innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Oncology

Expression of CD39 Identifies Activated Intratumoral CD8+T Cells in Mismatch Repair Deficient Endometrial Cancer

Joyce M. Lubbers, Marta A. Wazynska, Nienke van Rooij, Arjan Kol, Hagma H. Workel, Annechien Plat, Sterre T. Paijens, Martijn R. Vlaming, Diana C. J. Spierings, Philip H. Elsinga, Edwin Bremer, Hans W. Nijman, Marco de Bruyn

Summary: Identification of CD8+ T cells that react to human cancer is important for immunotherapy stratification and assessment of immune-therapeutic effects. In this study, a subset of CD103- CD39+ CD8+ T cells from mismatch repair-deficient endometrial tumors were found to be predominantly characterized by expression of TNFRSF9. These cells were recently activated and likely rapidly differentiated towards tissue residence upon exposure to TGF-beta in the tumor micro-environment, explaining their relative paucity in human tumors.

CANCERS (2022)

Article Biochemistry & Molecular Biology

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma

Jimena Alvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena Gonzalez Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer

Summary: This study investigates the expression and therapeutic effects of CD24 and CD47, two immune checkpoints, in B-cell lymphoma. The results show that CD24 is associated with poor survival in MCL patients, while CD47 is associated with survival in DLBCL patients. CD24 antibody treatment exhibits potent phagocytic effects in MCL, but not in DLBCL.

BIOMEDICINES (2022)

Article Oncology

The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling

Vrouyr Bilemjian, Martijn R. Vlaming, Jimena Alvarez Freile, Gerwin Huls, Marco De Bruyn, Edwin Bremer

Summary: This article investigates the role of the GPR56 immune checkpoint in tumor infiltrating lymphocytes in epithelial ovarian cancer. The expression of GPR56 differs between cancer and healthy cells, and ectopic expression of GPR56 reduces T cell migration.

CANCERS (2022)

Review Oncology

CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies

Renee Bouwstra, Tom van Meerten, Edwin Bremer

Summary: The CD47-SIRP alpha 'don't eat me' signaling axis is a prominent innate immune checkpoint, but monotherapy has limited therapeutic effect and severe side effects. Promising clinical responses have been seen with combination therapy, but toxicity issues remain. Innovations include novel antibody formats targeting CD47 on tumor cells and tumor-targeted bispecific antibodies. Combinatorial approaches with opsonizing antibodies, systemic therapy, epigenetic drugs, T-cell-targeted therapeutics, or dual immunomodulatory CD47 bispecific antibodies aim to improve the therapeutic effect of CD47 blockade.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

Article Immunology

Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival

Martijn Vlaming, Vrouyr Bilemjian, Jimena Alvarez Freile, Vinicio Melo, Annechien Plat, Gerwin Huls, Hans W. Nijman, Marco de Bruyn, Edwin Bremer

Summary: Reactivation of tissue-resident memory T cells expressing TIM-3 and CXCL13 in epithelial ovarian cancer is associated with improved patient survival, suggesting a potential therapeutic target for anti-cancer immunotherapy in EOC patients.

FRONTIERS IN IMMUNOLOGY (2022)

Article Biology

The DNA damage response pathway regulates the expression of the immune checkpoint CD47

Lucy Ghantous, Yael Volman, Ruth Hefez, Ori Wald, Esther Stern, Tomer Friehmann, Ayelet Chajut, Edwin Bremer, Michal Dranitzki Elhalel, Jacob Rachmilewitz

Summary: CD47 is upregulated following DNA damage, including irradiation, which depends on the key factor Mre11 in the DNA damage response pathway. CD47 is a cell surface ligand expressed on all nucleated cells and acts as an immune checkpoint protein to prevent phagocytosis. It is constitutively overexpressed in many tumors, but the underlying mechanism(s) for CD47 overexpression is unclear.

COMMUNICATIONS BIOLOGY (2023)

Article Gastroenterology & Hepatology

Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical Study

Kai Li, Yusheng Lin, Yu Zhou, Xiao Xiong, Lu Wang, Junkuo Li, Fuyou Zhou, Yi Guo, Shaobin Chen, Yuping Chen, Hui Tang, Xiaofu Qiu, Songwang Cai, Dianzheng Zhang, Edwin Bremer, Sai-Ching Jim Yeung, Hao Zhang

Summary: This study aims to establish a biomarker for early detection and risk stratification of esophageal squamous cell carcinoma (ESCC) using microRNA (miRNA) derived from salivary extracellular vesicles and particles (EVPs). The study identifies a 6-miRNA signature that accurately distinguishes patients with early-stage ESCC from control subjects, and successfully validates its effectiveness.

GASTROENTEROLOGY (2023)

Article Immunology

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Jimena Alvarez Freile, Yuzhu Qi, Lisa Jacob, Maria Franceskin Lobo, Harm Jan Lourens, Gerwin Huls, Edwin Bremer

Summary: Investigations into the strength of antigen-specific responses in vitro are crucial for early-phase research of immunotherapeutic approaches. This study presents a rapid luminescence-based method using HPV16 E7(11-20) peptide as a model antigen to evaluate MHC-dependent antigen-specific T cell responses in vitro. The method has important implications for assessing the impact of tumor microenvironment and immune checkpoint inhibitors, as well as accelerating the development of novel immunotherapies.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, Edwin Bremer

Summary: A bispecific antibody, CD27xEGFR, has been developed to re-activate T cell immunity in EGFR-expressing cancers through targeted co-stimulation of CD27. CD27xEGFR binds to both CD27 and EGFR simultaneously, triggering EGFR-restricted co-stimulation of T cells and enhancing T cell cytotoxicity against cancer cells. It has the potential to improve clinical outcomes in various cancers by overcoming the inhibitory factors that suppress T cell activity.

FRONTIERS IN IMMUNOLOGY (2023)

Article Cell Biology

Notch1 promotes resistance to cisplatin by up-regulating Ecto-5′-nucleotidase (CD73) in triple-negative breast cancer cells

Yuzhu Qi, Meifang Li, Shaozhong Li, De Zeng, Yingsheng Xiao, Jiwei Li, Qianqian Ye, Edwin Bremer, Guo-jun Zhang

Summary: This study explored the molecular mechanisms of chemoresistance in triple-negative breast cancer (TNBC) and found that Notch1 and CD73 were associated with poor clinical outcome in cisplatin-treated patients. Further experiments revealed that Notch1 regulated CD73 expression by directly binding to the CD73 promoter. These findings suggest that CD73 is a direct downstream target of Notch1 in mediating cisplatin resistance in TNBC.

CELL DEATH DISCOVERY (2023)

Article Cell Biology

Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance

Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer, Valerie R. Wiersma

Summary: AML is a malignancy associated with poor survival rates, especially due to therapy-resistant relapse. The glycan-binding protein Gal-9 has shown tumor-selective cytotoxicity, dependent on autophagy inhibition, making it a potential therapeutic option for AML. In this study, Gal-9 was found to be cytotoxic for AML cells, including stem cells, and showed efficacy in AraC-resistant AML cases. It also enhanced the cytotoxic effect of Azacytidine, providing a possible treatment approach for AML patients not eligible for intensive AraC treatment.

CELL DEATH DISCOVERY (2023)

暂无数据